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based on revealing of xenobiotics to influence on specific
enzymes participating in epigenetic modifications, especially
DNA methylation and histone modifications. Recently a new
model system for the screening of compounds reactivating
epigenetically repressed genes was described. It represents HeLa
cell population that harbors silent GFP-reporter gene which could
be activated via different epigenetic mechanisms.
Epigenetic studies of xenobiotic-induced mechanisms will
reveal valuable information clarifying both mechanisms of desir-
able therapy and side effects and open potential drug design
directions. The major challenge that remains is to determine
how epigenetic control is regulated and how it might be possible
to intervene in such processes.
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Oncolytic virus therapy is an area in experimental cancer ther-
apy that is under active investigation. A wide variety of viruses
have shown huge potent oncolytic activity against human tumors
in cell and animal models without major side effects. Several
strains have already being tested in clinical trials in patients.
Virotherapy is making promising progress for the treatment of
malignancies. Nonetheless, when used in patients, the response
rate to oncolytic virus is low. One of the main ways to increase
oncolytic capacity is to refuse of excessive attenuation and to
use the wild type of oncolytic strains.
Naturally occurring oncolytic viruses (OVs) have shown their
high cancer-targeted antitumor effects with selectively replica-
tion and destroying tumor cells while sparing normal cells,
because of defects in IFN-signaling pathways in tumor cell lines.
Newcastle disease virus (NDV) is one of the promising thera-
peutic agent for virotherapy. It belongs to avian paramyxovirus
(APMV-1) that is able to infect over 240 species of birds and induce
severe disease. However, NDV is not a human pathogen.
Newcastle disease virus exhibits effectively oncolytic activity in
a range of tumors in pre-clinical and clinical studies. We have
previously reported in vitro oncolytic effects of three wild NDV
strains. Here we demonstrate data that describe oncolytic capac-
ity NDV collection gathered in 2008–2014, Russia. Antitumor
effect of NDV strains on a panel of tumor human cell lines
(HCT116, MCF7, A549, HeLa, Skbr, H1299) were investigated. Cell
viability was examined over 96 hours by MTT assay. Dose-
dependent cell cytotoxicity was demonstrated.
In vitro study shows the capacity of several wild NDV strains
to lyse tumor cell lines. Two strains of them have significant
strong oncolytic activity on human tumor cells of various
histogenesis.
Recent work in our research also describes the results of
in vivo experiments. One of them consists of comparing the effi-
cacy of NDV strain to exhibit specific oncolytic activity in C57Bl/6
mice on subcutaneous murine tumors (LLC and B16) . Our results
show that both intravenous and intratumoral injections with
multiple doses of wild NDV strain lead to survival prolongation
in B16- and LLC-bearing mice and prevent tumor development.
We demonstrate antitumor activity of NDV/Altai/
pigeon/770/2011 against murine KREBS-2 solid tumor in preclini-
cal model on immunocompetent BALB/c mice. Recently we have
demonstrated that NDV/Altai/pigeon/770/2011 can destroy
murine KREBS-2 cells in vitro. Moreover, in pilot study we have
shown that intratumoral NDV injections decrease of tumor
volume and result in complete regression of KREBS-2 tumor in
MRI images.
Here we test intratumoral administration of NDV and show
suppression of Krebs-2 tumor growth in intramuscularly allograft
model (2.6-fold less size that in untreated group). Importantly,
spread of the virus causes significant tumor necrosis in Krebs-2
tumors. By 20 days after virotherapy, widespread necrosis of
NDV-treated tumor is observed. We describe that the vast fields
of necrosis in NDV-treated group are the results of formation of
ischemic foci in tumor tissue with the rapid development of
tumor node and slow neoangiogenesis.
Histological examinations and morphometric analysis of
tumors in NDV-treated and control groups show that the number
of blood vessels including the newly formed in the untreated
group is significantly higher than in the experimental group.
Immunohistochemical staining (CD34, VEGFR) shows that blood
vessels in tumor tissue is strongly reduced to 20 days post-
treatment and neoangiogenesis progresses in untreated tumor
tissue.
Thus, results suggest that vascular disruption in the
NDV-treated group indicates the virus ability to directly or indi-
rectly affect tumor angiogenesis and regulate tissue trophism in
that way. Understanding how and in which step this effect occurs
may provide capacity to use oncolytic NDV strains for therapeutic
benefit.
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The mechanisms of mesenchymal stem cells (MSC) action on
malignant neoplasms attract much attention nowadays. Studies
relating to the MSC effect on tumors are contradictory and
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